News and updates for Opal Therapeutics and research into reproductive health

  • Opal Awarded $1.25 million NSF SBIR Phase II

    Opal Awarded $1.25M NSF SBIR

    August 6th, 2026

    Opal was awarded a prestigious NSF SBIR grant to expand their uterine organoid infrastructure for women’s reproductive health therapeutics and diagnostics

    Full Press Release
  • Opal Therapeutics and VerisimLife Logos

    Opal Win's Phase I of NIH's Complement-ARIE Challenge

    July 20th, 2026

    In partnership with VeriSIMLife, Opal has won the NIH’s Complement Animal Research in Experimentation NAMs Challenge!

    Read More
  • Podcast: Overlooked, Women's Health Can't Wait

    How Menstrual Blood Will Revolutionize Women’s Health Research

    October 1, 2025

    In this Overlooked podcast episode, Morgan Stanton shares how cells from menstrual blood are transforming research on fibroids and endometriosis.

    Full Podcast
  • SFTechWeek Opal Therapeutics Event

    Spark & Build: Women’s Health Startup Sprint

    September 17th, 2025

    During SF Tech Week, Opal Therapeutics hosted a hackathon at their labs in San Francisco. In 2 hours we had some amazing women’s health companies!

    Photos from Event
  • 2025 CLS FAST Program Cohort

    Opal Therapeutics joins the CLS FAST 2025 Cohort!

    September 10, 2025

    Opal Therapeutics is joining the CLS FAST 2025 Accelerator Program to help fast-track innovation in women’s health through organoid-based drug discovery.

    Learn More About CLS
  • VC Investment in Women's Health

    Women's Health 2.0: Beyond Fertility

    August 14, 2025

    The VC firm, NFX, highlight’s Opal Therapeutic’s organoid biobank for reproductive cells and improving drug discovery and discusses what’s next women’s health.

    Full Article
  • Morgan Stanton featured at Aspen Ideas

    Aspen Health Fellows Spotlight: Morgan Stanton

    June 13, 2025

    Aspen Ideas featured Opal CEO, Morgan Stanton, and her work on uterine organoids to improve reproductive health

    Full Interview
  • Opal Therapeutics, NSF I-Corps

    Opal participates in the NSF I-CORPs program

    May 8th, 2025

    Opal is proud to participate in the NSF I-Corps program to accelerate innovation in women’s health through advanced organoid models

    NSF I-CORPs
  • Presentation of Endometriosis Model

    Opal invited to pitch at MBC Women's Health Forum

    April 24th, 2025

    MBC Biolabs hosted a Women’s Health Innovation Forum where Opal showcased some of their new work in endometriosis.

    LinkedIn Post
  • WPI Cover Story - Opal Therapeutics

    WPI Journal Cover Story - Opal Therapeutics!

    February 6th, 2025

    Opal CEO, Morgan Stanton is featured in the WPI Journal and discusses why we need to make major changes in addressing women’s health R&D.

    Full WPI Article
  • CEO, Morgan Stanton at Techstars Demo Day

    Opal Therapeutics arrives at Techstars Demo Day!

    December 6th, 2024

    All Opal’s hard work has paid off! See CEO, Morgan Stanton, be the first pitch at Techstars San Franciso Demo Day.

    Pitch Video
  • NSF SBIR

    Opal awarded NSF SBIR Grant

    August 22, 2024

    Opal is proud to annouce they are the recipient of a Phase I NSF SBIR grant for their research into therapeutic development for women’s health

    NSF Award